Phase II Reactions: Glucuronidation
Hepatic Drug Excretion: Influencing Factors
Liver Regeneration
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
Drug Metabolism: Phase II Reactions
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
您也可能阅读
通过共同作者、期刊和引用图与本文相关的文章。
Updated: Sep 9, 2025

Cell Type-specific Gene Expression Profiling in the Mouse Liver
Published on: September 17, 2019
Joanne Lin1,2, David Braxton3, Tse-Ling Fong4
1Hoag Digestive Health Institute, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA joanne.lin@ucsf.edu.
这项病例研究突出了一个罕见的发酵剂诱导的肝损伤病例. 监测肝功能对于服用febuxostat的患者至关重要.
科学领域:
背景情况:
研究的目的:
主要方法:
主要成果:
结论: